What package, storage conditions and retest period are recommended
BioMed Central Lin HT et al
The proportion of patients who completed treatment with rescue medication varied across trials, but was consistently lower with oral semaglutide 7 mg, 14 mg, and flexibly dosed (026% across background medication subgroups) than comparator treatments (734%), whereas the proportion of patients who discontinued the trial product was often somewhat higher (1225% vs 515% except when sitagliptin was added to multiple background medications in PIONEER 7 [50% in a very small subgroup of 8 patients]) (see Table S1 in the Supplementary Information)
[4] Ultimately, the choice of GLP-1 agonist should be a collaborative decision between the patient and their healthcare provider, taking into account individual factors, treatment goals, and potential risks and benefits
Our telehealth-first model means you can manage your doses, ask questions about timing, and track your progress all from the comfort of your home